10:08 AM EDT, 06/25/2025 (MT Newswires) -- GlucoTrack ( GCTK ) said Wednesday the first human trial of its continuous blood glucose monitor met all primary and secondary endpoints, demonstrating 'excellent accuracy.'

The study involved ten participants with either Type 1 or Type 2 diabetes who were on intensive insulin therapy. The percutaneous installed device showed strong accuracy with a 7.7% mean absolute relative difference, a 99% data capture rate, and no serious adverse events. Unlike traditional systems, it measures glucose directly from blood, reducing lag time, the medical device company said.

Glucotrack ( GCTK ) said it plans to launch a longer-term feasibility study in the third quarter of 2025 to further evaluate the device's safety and performance.

Shares of GlucoTrack ( GCTK ) were up more than 60% in recent Wednesday trading.

Price: 10.46, Change: +4.25, Percent Change: +68.44